Scholarly Index
Hiroaki Nagano
Chugai Pharma (United States); 18,281 total citations; 678 total publications; best world rank #159
Chugai Pharma (United States)
18,281Total citations
678Total publications
69H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 226 | US 72 | 99.14 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 233 | US 82 | 98.91 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 550 | US 255 | 98.70 |
| Cancer Mechanisms and Therapy | Lifetime | 159 | US 79 | 98.28 |
| Organ Transplantation Techniques and Outcomes | Lifetime | 764 | US 330 | 97.91 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 318 | US 69 | 94.61 |
| Gallbladder and Bile Duct Disorders | 2021-2025 | 789 | US 154 | 89.25 |
| Cardiac tumors and thrombi | 2021-2025 | 779 | US 241 | 70.04 |